Histogenics (NASDAQ:HSGX) posted its quarterly earnings results on Thursday, March 15th. The biotechnology company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.31) by $0.05, Bloomberg Earnings reports.
Shares of NASDAQ HSGX opened at $2.80 on Friday. Histogenics has a 52 week low of $1.59 and a 52 week high of $3.35. The stock has a market capitalization of $81.47, a price-to-earnings ratio of -2.86 and a beta of 1.69.
Hedge funds and other institutional investors have recently modified their holdings of the business. Virtu Financial LLC boosted its stake in Histogenics by 413.4% in the 4th quarter. Virtu Financial LLC now owns 63,563 shares of the biotechnology company’s stock worth $130,000 after purchasing an additional 51,182 shares during the period. Deutsche Bank AG boosted its stake in Histogenics by 71.1% in the 4th quarter. Deutsche Bank AG now owns 71,706 shares of the biotechnology company’s stock worth $146,000 after purchasing an additional 29,806 shares during the period. Renaissance Technologies LLC boosted its position in shares of Histogenics by 54.8% during the 4th quarter. Renaissance Technologies LLC now owns 242,500 shares of the biotechnology company’s stock valued at $497,000 after acquiring an additional 85,800 shares during the last quarter. Finally, Sabby Management LLC boosted its position in shares of Histogenics by 98.3% during the 4th quarter. Sabby Management LLC now owns 955,060 shares of the biotechnology company’s stock valued at $1,958,000 after acquiring an additional 473,393 shares during the last quarter. Institutional investors and hedge funds own 42.96% of the company’s stock.
HSGX has been the subject of several analyst reports. HC Wainwright set a $4.00 target price on Histogenics and gave the stock a “buy” rating in a research note on Wednesday, December 27th. Zacks Investment Research downgraded Histogenics from a “hold” rating to a “sell” rating in a research note on Wednesday, January 24th. ValuEngine upgraded Histogenics from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd. Finally, Canaccord Genuity restated a “buy” rating and issued a $4.00 target price on shares of Histogenics in a research note on Thursday, December 21st.
COPYRIGHT VIOLATION NOTICE: This news story was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this news story on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark legislation. The correct version of this news story can be read at https://www.dispatchtribunal.com/2018/04/07/histogenics-hsgx-posts-earnings-results-beats-estimates-by-0-05-eps.html.
Histogenics Company Profile
Histogenics Corporation, a regenerative medicine company, focuses on developing and commercializing products in the musculoskeletal segment of the marketplace in the United States. The company offers NeoCart, a tissue implant, which is in Phase III clinical trial to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.
Receive News & Ratings for Histogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogenics and related companies with MarketBeat.com's FREE daily email newsletter.